Sab biotherapeutics announces positive results from phase 3 trial of sab-185 in patients with covid-19 at high-risk for severe complications

Sab-185, a human igg1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with omicron variants of sars-cov-2 sab-185, a human igg1 (polyclonal) antibody therapeutic candidate, demonstrated benefit in sustained symptom resolution in patients with omicron variants of sars-cov-2
SABS Ratings Summary
SABS Quant Ranking